The race to develop a vaccine to fight the novel coronavirus is like any other competition. There are going to be winners and losers. It appears iBio (NYSEAMERICAN:IBIO) will be in the latter the camp despite the fact that IBIO stock is up 691% this year. Source: Shutterstock On balance, a 691% gain in less
Stocks to sell
I pounded the table for Advanced Micro Devices (NASDAQ:AMD) six years ago, when it named Dr. Lisa Su as CEO. I liked AMD stock at $20, and even $40. It’s a great company. She’s a great leader. AMD makes faster microprocessors than Intel (NASDAQ:INTC). It’s competitive in graphics with Nvidia (NASDAQ:NVDA). Source: Casimiro PT /
The steep decline of Inovio (NASDAQ:INO) stock is continuing. Earlier this year, Inovio electrified traders when it announced that it had a potential vaccine candidate for the novel coronavirus. Following the disclosure, INO stock shot up to as high as $33 this summer, versus its 52-week low of $1.92. Source: Ascannio / Shutterstock.com However, the
Zoom (NASDAQ:ZM) stock surged to all -time highs in early September after the enterprise video conferencing company reported blowout second-quarter numbers which were about as strong as you could imagine. Source: Michael Vi / Shutterstock.com Customers rose 458% in the quarter. Revenues rose 355%. Operating margins tripled. Net profits rose more than ten-fold. It was,
Its been the year of the special purpose acquisition company (SPAC). Over 50 SPACs have been formed in 2020 alone, and they have raised over $21.5 billion. Spartan Energy Acquisition (NYSE:SPAQ) is one of the top SPACs in the market, as SPAQ stock has jumped 40% so far this year. Source: Shutterstock The company’s big
Chances are, you’re probably not going to find too many bullish takes on Naked Brand Group (NASDAQ:NAKD) stock. Source: Shutterstock On the surface, Naked Brand offers relevant products. As you probably know, the company specializes in undergarments and lingerie, with perhaps its most popular brand being Frederick’s of Hollywood. Yet despite the attractiveness of its
In a prior article, I said that Docusign (NASDAQ:DOCU) was a company that will continue to grow regardless of the pandemic. Secure, electronic signatures are simply an idea whose time has come. And it has become essential technology for many online businesses. But should you buy Docusign stock at its current price? The technicals are